Mizuho started coverage on shares of Audentes Therapeutics (NASDAQ:BOLD) in a research note issued to investors on Monday, MarketBeat reports. The firm issued a neutral rating and a $26.00 price target on the biotechnology company’s stock.
A number of other brokerages have also weighed in on BOLD. Raymond James Financial restated a hold rating on shares of Audentes Therapeutics in a report on Thursday, January 4th. William Blair restated a buy rating on shares of Audentes Therapeutics in a report on Friday, January 5th. BMO Capital Markets set a $44.00 price objective on shares of Audentes Therapeutics and gave the company a buy rating in a report on Friday, January 5th. Zacks Investment Research lowered shares of Audentes Therapeutics from a hold rating to a sell rating in a report on Monday, January 22nd. Finally, Wedbush raised their price objective on shares of Audentes Therapeutics to $56.00 and gave the company an outperform rating in a report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $34.00.
Shares of Audentes Therapeutics (NASDAQ:BOLD) opened at $32.82 on Monday. Audentes Therapeutics has a fifty-two week low of $13.90 and a fifty-two week high of $41.80.
Several hedge funds and other institutional investors have recently bought and sold shares of BOLD. Vanguard Group Inc. grew its position in shares of Audentes Therapeutics by 130.3% in the 2nd quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after buying an additional 383,837 shares during the last quarter. Farallon Capital Management LLC purchased a new position in shares of Audentes Therapeutics in the 4th quarter valued at $9,989,000. Citadel Advisors LLC grew its position in shares of Audentes Therapeutics by 206.2% in the 4th quarter. Citadel Advisors LLC now owns 339,588 shares of the biotechnology company’s stock valued at $10,612,000 after buying an additional 228,667 shares during the last quarter. Artal Group S.A. purchased a new position in shares of Audentes Therapeutics in the 3rd quarter valued at $5,602,000. Finally, BlackRock Inc. grew its position in shares of Audentes Therapeutics by 13.2% in the 4th quarter. BlackRock Inc. now owns 1,358,498 shares of the biotechnology company’s stock valued at $42,452,000 after buying an additional 158,576 shares during the last quarter. 64.94% of the stock is currently owned by hedge funds and other institutional investors.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.